Edition:
United Kingdom

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

91.96USD
15 Dec 2017
Change (% chg)

$3.21 (+3.62%)
Prev Close
$88.75
Open
$88.91
Day's High
$93.41
Day's Low
$88.50
Volume
1,389,973
Avg. Vol
145,940
52-wk High
$93.41
52-wk Low
$15.19

Chart for

About

AnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in... (more)

Overall

Beta: --
Market Cap(Mil.): $725.82
Shares Outstanding(Mil.): 20.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Anaptysbio qtrly loss per share $0.45‍​

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates

07 Nov 2017

BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results

* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results

06 Nov 2017

BRIEF-AnaptysBio prices public offering of 3 mln shares at $68.50 per share

* Says public offering of 3.00 million common shares priced at $68.50per share Source text for Eikon: Further company coverage:

13 Oct 2017

BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis

* AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis

10 Oct 2017

BRIEF-‍adage Capital reports a 6.05 percent passive stake in AnaptysBio

* ‍Adage Capital Partners GP reports a 6.05 percent passive stake in AnaptysBio Inc​ as of September 22 - SEC filing​ Source text: (http://bit.ly/2yTdILI) Further company coverage:

02 Oct 2017

BRIEF-AnaptysBio reports about 19 pct rise in Q2 revenue

* AnaptysBio announces second quarter 2017 financial results and provides pipeline updates

10 Aug 2017

Earnings vs. Estimates